Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 52,700 shares, a growth of 51.0% from the August 31st total of 34,900 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 54,300 shares, the short-interest ratio is presently 1.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PSTV. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a research report on Friday, August 16th. Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC bought a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Price Performance

Shares of NASDAQ:PSTV traded up $0.31 during trading on Friday, reaching $1.85. 370,333 shares of the company were exchanged, compared to its average volume of 56,610. The firm has a market capitalization of $10.55 million, a PE ratio of -0.61 and a beta of 0.65. The business’s fifty day simple moving average is $1.55 and its 200-day simple moving average is $1.78. Plus Therapeutics has a 12-month low of $0.97 and a 12-month high of $2.78.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share for the quarter. The firm had revenue of $1.28 million during the quarter. Plus Therapeutics had a negative net margin of 240.15% and a negative return on equity of 805.57%. On average, sell-side analysts anticipate that Plus Therapeutics will post -2.22 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.